5/29/2026
Executives at this Minnesota Company Commute Here by Plane. A Shareholder Wants to Change That.
Minnesota Star Tribune (05/29/26) Kennedy, Patrick
Most or all of Solventum’s (NYSE: SOLV) top leadership team, including CEO Bryan Hanson, live out of state, and one of its major shareholders is fighting the company over it. “We have never seen a situation like this where an entire C-suite is effectively remote,” the investor, Trian Fund Management, wrote in an open letter to the board in April. “In our view, this is not how strong organizations are built.” “We also expect this management team to start working together from one central headquarters and to stop commuting to work by private aircraft,” Trian wrote. “Shareholders are paying for this.” Trian said that besides Hanson, who lives in Florida, Solventum’s chief financial, commercial, human resources and transformation officers live in Connecticut, Illinois, Ohio, and Massachusetts, respectively. In addition, the presidents of its three main units — MedSurg, Health Information Systems and Dental Solutions — do not live in the same cities as the businesses are based. Trian officials declined to comment on details of the campaign. Solventum, too, declined to comment on whether its executives being outside Minnesota affected performance. But Trian in its latest letter said the health care company has done more to maximize compensation for a remote management team than increase shareholder value. Solventum, it said, has not delivered on its potential. The letters note that before the spinoff from 3M (NYSE: MMM), analysts estimated that a post-spin Solventum would have a market capitalization of $25 billion. Instead, it is $13 billion. The stock has had a total return of 11% since its inception, and its current market cap is $13.3 billion. Meanwhile, 3M’s total return has been nearly 70% since the spinoff. Analysts from Baptista Research in May characterized the Solventum-Trian back-and-forth as a conflict between a newly independent company and an aggressive investor. “The central question is whether Solventum needs more time or more pressure,” they wrote. Trian’s latest letter might have swayed a “say-on-pay” vote at Solventum’s May 14 annual meeting. The nonbinding advisory proposal on the company’s executive compensation program passed with 74% voting in favor. Average shareholder support at S&P 500 companies for say-on-pay votes is 91% this year, according to Semler Brossy, an independent consulting firm that tracks executive pay. Trian is a multibillion-dollar investment fund that was founded in 2005 by Nelson Peltz and Peter May. It controls about 5% of Solventum’s stock, which it acquired after company spun off from 3M Corp. in April 2024. Trian in 2024 proposed adding someone associated with the investment fund to the board. In 2025, it suggested adding an additional independent director nominated by Trian who has been CEO of a Fortune 100 health care company. Solventum declined both recommendations. In its April letter, Trian suggested three main avenues for change. The investment fund wants Solventum to more aggressively cut overhead costs, streamline its portfolio of businesses and be more aggressive buying back its own shares, which Trian says are currently undervalued. Solventum said the company welcomes input from shareholders and will continue to engage with them and increase shareholder value. “Since spinning in April 2024, Solventum has acted with urgency and delivered meaningful progress against a clear three-phased transformation to stabilize the business, enhance strategic focus and optimize the portfolio, while executing a highly complex separation," said Brad Puffer, a Solventum spokesperson. Trian also took issue with Hanson’s compensation at Solventum. “The CEO has already been paid more than $80 million in just over two years, while the business has gone backwards,” Trian wrote. (That total includes grant date values of long-term equity awards.) Trian questions why the management team doesn’t take fuller advantage of its headquarters, surrounding talent and the proximity to other leading public companies such as Medtronic (NYSE: MDT), UnitedHealth (NYSE: UNH), 3M, and Fastenal (NASDAQ: FAST). Solventum is not the only company with a remote CEO, and the value of having a chief executive live where a multinational company is based has been debated. A lot of travel is part of a Fortune 500 executive’s job. For example, James Cracchiolo, CEO of Ameriprise (NYSE: AMP), one of the best-performing Minnesota-based companies, lives in New Jersey. Former Target (NYSE: TGT) CEO Brian Cornell lived in Florida at least part of his time running the company. Yet Dave Bozeman of C.H. Robinson (NASDAQ: CHRW) and Linda Findley of Sleep Number Corp. (NASDAQ: SNBR) both chose to move to Minnesota, noting the need to be close at hand to guide turnarounds at those companies. Lauren D’Innocenzo, professor of organizational behavior at Drexel University’s LeBow College of Business, said there are pros and cons to being remote. The key for C-suite executives is how they present themselves, she said. “I’d never advocate for 100% remoteness, especially for C-suites,” D’Innocenzo said. “There needs to be some active in-person involvement as well." If executives are remote, they need to be purposeful and intentional in showing up at key company events, she said. In those moments, asking employees how they can serve them is more effective than asking what or how employees are doing things. “When you’re remote, you want to manage those perceptions that employees have,” D’Innocenzo said. In 2025, Solventum had annual revenue of $8.3 billion, with 58% of revenue coming from its MedSurg segment that makes wound care products, surgical supplies, medical tapes and stethoscopes. Trian wants Solventum to focus on the MedSurg business and “immediately” divest its dental unit (16% of 2025 sales) and health information systems business (16% of 2025 sales). Michael Piccolo, an analyst with Wedbush Securities, recently initiated coverage on Solventum with a “buy” recommendation that referenced Trian’s view of Solventum’s portfolio. “Our investment thesis centers on the divestiture and/or spin-off of non-core health information systems and dental solutions segments,” Piccolo wrote. “We believe the probability of near-term portfolio action is high.”
Read the article